XML 25 R18.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Net Loss per Share | 6 Months Ended
--- | ---
Jun. 30, 2024
Earnings Per Share [Abstract] |
Net Loss per Share | Note 9: Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to Class A ordinary shareholders by the weighted-average shares of Class A ordinary shares outstanding without the consideration for potential dilutive securities. Diluted net loss per share represents basic net loss per share adjusted to include the effects of all potentially dilutive shares. Diluted net loss per share is the same as basic loss per share for all periods as the inclusion of potentially issuable shares would be antidilutive. The following table sets forth the computation of basic and diluted net loss per share for the three months ended June 30, 2024 and 2023 (in thousands, except share and per share amounts):
| Three Months Ended June 30, |  |  | For the Six Months Ended June 30, |
| 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Numerator |  |  |  |  |  |  |  |  |  |  |
Net loss | $ | (38,466 | ) |  | $ | (34,823 | ) |  | $ | (73,799 | ) |  | $ | (71,732 | )
Less: Net loss attributable to noncontrolling interests |  | (25,960 | ) |  |  | (25,705 | ) |  |  | (51,801 | ) |  |  | (52,949 | )
Net loss available to Class A ordinary shareholders of ProKidney Corp., basic and diluted | $ | (12,506 | ) |  | $ | (9,118 | ) |  | $ | (21,998 | ) |  | $ | (18,783 | )
Denominator |  |  |  |  |  |  |  |  |  |  |
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, basic and diluted |  | 75,908,017 |  |  |  | 64,562,209 |  |  |  | 68,429,869 |  |  |  | 64,551,281 |
Net loss per Class A ordinary share |  |  |  |  |  |  |  |  |  |  |
Net loss per Class A ordinary share of ProKidney Corp., basic and diluted | $ | (0.16 | ) |  | $ | (0.14 | ) |  | $ | (0.32 | ) |  | $ | (0.29 | )
Outstanding anti-dilutive securities not included in the diluted net loss per share calculation include the following:
| As of June 30, |
| 2024 |  |  | 2023 |
Antidilutive securities |  |  |  |  |
ProKidney Corp. Class B ordinary shares |  | 163,817,953 |  |  |  | 173,663,427 |
Unvested Restricted Stock Rights |  | 2,188,728 |  |  |  | 5,952,288 |
Earnout Rights |  | 17,500,000 |  |  |  | 17,500,000 |
Stock options granted under the 2022 Equity Incentive Plan |  | 21,916,121 |  |  |  | 15,718,932 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration